Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

Rhea-AI Summary

Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company focused on developing transformative medicines for immune and inflammatory diseases, has announced its participation in the upcoming Leerink's Global Healthcare Conference 2025.

The company's Co-Founder and CEO, Sandeep Kulkarni, MD, will engage in a fireside chat scheduled for Tuesday, March 11, 2025, at 4:20 pm ET in Miami. Interested parties can access both the live webcast and replay through the 'Events and Presentations' section under News & Investors on Tourmaline Bio's website at ir.tourmalinebio.com.

News Market Reaction – TRML

-5.81%

-5.81% Session move

In the trading session that priced this news, TRML declined 5.81%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:

Leerink's Global Healthcare Conference 2025, Miami
Fireside Chat
Tuesday, March 11, 2025, at 4:20 pm ET

A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com.

About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X.

Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com  

Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com

FAQ

When is Tourmaline Bio (TRML) presenting at the Leerink Global Healthcare Conference 2025?

Tourmaline Bio will present on Tuesday, March 11, 2025, at 4:20 pm ET in Miami.

How can investors watch Tourmaline Bio's (TRML) presentation at the Leerink Conference?

Investors can access the live webcast and replay through the 'Events and Presentations' section at ir.tourmalinebio.com.

What type of diseases does Tourmaline Bio (TRML) focus on treating?

Tourmaline Bio focuses on developing medicines for life-altering immune and inflammatory diseases.

Who will represent Tourmaline Bio (TRML) at the Leerink Healthcare Conference 2025?

Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, will represent Tourmaline Bio.